OptimizeRx (OPRX) 10-Q 14 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 13, 2013
Document And Entity Information	'	'
Entity Registrant Name	'OptimizeRx Corp	'
Entity Central Index Key	'0001448431	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	14,503,496
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current Assets	'	'
Cash and cash equivalents	$486,692	$284,263
Accounts receivable	1,148,907	616,798
Prepaid expenses	26,336	68,158
Total Current Assets	1,661,935	969,219
Property and equipment, net	16,464	20,685
Other Assets	'	'
Patent rights, net	788,890	793,236
Web development costs, net	351,778	387,215
Security deposit	5,049	5,049
Total Other Assets	1,145,717	1,185,500
TOTAL ASSETS	2,824,116	2,175,404
Current Liabilities	'	'
Accounts payable - trade	174,453	54,693
Accounts payable - related party	570,000	570,000
Accrued expenses	0	6,000
Deferred revenue	13,272	49,252
Total Liabilities	757,725	679,945
Stockholders Equity	'	'
Common stock, $.001 par value, 500,000,000 shares authorized, 14,752,496 and 14,232,496 shares issued and outstanding	14,752	14,232
Preferred stock, $.001 par value, 10,000,000 shares authorized, 65 shares issued and outstanding	0	0
Stock warrants	18,316,826	20,058,051
Additional paid-in-capital	8,449,271	6,164,666
Deferred stock compensation	-233,077	0
Accumulated deficit	-24,481,381	-24,741,490
Total Stockholders Equity	2,066,391	1,495,459
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$2,824,116	$2,175,404

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Common Stock, Par Value	$0.00	$0.00
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Issued	14,752,496	14,232,496
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Issued	65	65

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
REVENUE	'	'	'	'
Sales	$1,373,029	$453,154	$3,146,406	$1,297,980
TOTAL REVENUE	1,373,029	453,154	3,146,406	1,297,980
EXPENSES	'	'	'	'
Operating expenses (See Note 17)	1,362,335	559,305	2,886,473	1,781,257
TOTAL EXPENSES	1,362,335	559,305	2,886,473	1,781,257
OPERATING INCOME (LOSS)	10,694	-106,151	259,933	-483,277
OTHER INCOME (EXPENSE)	'	'	'	'
Interest income	82	77	176	408
Interest expense	0	-100	0	-100
TOTAL OTHER INCOME (EXPENSE)	82	-23	176	308
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES	10,776	-106,174	260,109	-482,969
PROVISION FOR INCOME TAXES	0	0	0	0
NET INCOME (LOSS)	$10,776	($106,174)	$260,109	($482,969)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC	14,270,811	14,227,713	14,259,675	14,201,373
NET INCOME (LOSS) PER SHARE: BASIC	$0	($0.01)	$0.02	($0.03)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: DILUTED	34,086,091	14,227,713	34,074,956	14,201,373
NET INCOME (LOSS) PER SHARE: DILUTED	$0	($0.01)	$0.01	($0.03)

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net income (loss) for the period	$260,109	($482,969)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:	'	'
Depreciation and amortization	144,562	140,087
Stock-based compensation	310,823	227,922
Changes in:	'	'
Accounts receivable	-532,109	-171,779
Prepaid expenses	41,822	74,140
Accounts payable	119,760	-328,236
Accrued expenses	-6,000	-66,000
Deferred revenue	-35,980	-18,831
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	302,987	-625,666
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Purchases of property and equipment	0	-2,230
Patent rights	-38,278	0
Web development costs	-62,280	-48,640
NET CASH USED IN INVESTING ACTIVITIES	-100,558	-50,870
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	202,429	-676,536
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	284,263	959,166
CASH AND CASH EQUIVALENTS - END OF PERIOD	486,692	282,630
SUPPLEMENTAL CASH FLOW INFORMATION:	'	'
Cash paid for interest	0	0
Cash paid for income taxes	0	0
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES:	'	'
Common stock issued in officer settlement upon severance	$505,000	$0

NATURE_OF_BUSINESS

NATURE OF BUSINESS	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
NATURE OF BUSINESS	'
	Optimizer Systems, LLC was formed in the State of Michigan on January 31, 2006. It then became a corporation in the State of Michigan on October 22, 2007 and changed its name to OptimizeRx Corporation. On April 14, 2008, RFID, Ltd., a Colorado corporation, consummated a reverse merger by entering into a share exchange agreement with the stockholders of OptimizeRx Corporation, pursuant to which the stockholders of OptimizeRx Corporation exchanged all of the issued and outstanding capital stock of OptimizeRx Corporation for 1,256,958 shares of common stock of RFID, Ltd., representing 100% of the outstanding capital stock of RFID, Ltd. As of April 30, 2008, RFID’s officers and directors resigned their positions and RFID changed its business to OptimizeRx’s business. On April 15, 2008, RFID, Ltd.’s corporate name was changed to OptimizeRx Corporation. On September 4, 2008, a migratory merger was completed, thereby changing the state of incorporation from Colorado to Nevada, resulting in the current corporate structure, in which OptimizeRx Corporation, a Nevada corporation, is the parent corporation, and OptimizeRx Corporation, a Michigan corporation, is a wholly-owned subsidiary (together, "OptimizeRx" and "the Company").
	The wholly-owned subsidiary, OptimizeRx Corporation, is a technology solutions company targeting the health care industry. Their objective is to bring better access to better care through connecting patients, physicians and pharmaceutical manufacturers through technology. Once defined as a marketing and advertising company through its consumer website, OptimizeRx is maturing as a technology solutions provider as it launched its direct to physician solution, SampleMD. SampleMD allows physicians to search, print and send available sample trial vouchers and/or co-pay coupons on behalf of their patients. The SampleMD solution can either sit on the doctor’s desktop or can be integrated into the ePrescribing or Electronic Medical Records applications. OptimizeRx solutions provide pharmaceutical manufacturers either a direct to consumer and/or direct to physician channels for communicating and promoting their products. It provides health care providers a means to provide sampling and coupons without having to physically store samples on site, and it provides better access and affordability to the patients.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	Basis of Presentation
	The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”), and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Form 10-K filed with the SEC as of and for the year ended December 31, 2012. In the opinion of management, all adjustments necessary for the financial statements to be not misleading for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year.
	Accounting Basis
	The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting). The Company has adopted a December 31 fiscal year end.
	Principles of Consolidation
	The financial statements reflect the consolidated results of OptimizeRx Corporation (a Nevada corporation) and its wholly owned subsidiary OptimizeRx Corporation (a Michigan corporation). All material inter-company transactions have been eliminated in the consolidation.
	Cash and Cash Equivalents
	For purposes of the accompanying financial statements, the Company considers all highly liquid instruments with an initial maturity of three months or less to be cash equivalents.
	Fair Value of Financial Instruments
	The fair value of cash, accounts receivable, prepaid expenses, patent rights, web development costs, accounts payable, accounts payable – related party, accrued expenses and deferred revenue approximates the carrying amount of these financial instruments due to their short-term nature. The fair value of long-term debt, which approximates its carrying value, is based on current rates at which the Company could borrow funds with similar remaining maturities.
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates. Bad debt expense was $0 for the nine months ended September 30, 2013 and 2012, respectively. The allowance for doubtful accounts was $0 as of September 30, 2013 and December 31, 2012, respectively.
	Property and Equipment
	The capital assets are being depreciated over their estimated useful lives, three to seven years using the straight-line method of depreciation for book purposes.
	Revenue Recognition
	All revenue is recognized when it is earned. Revenues are generated either through the Company’s website activities, in which we earn revenue from advertising and lead generation activities, or from our SampleMD activities, which include offering setup within the systems and our offers, coupons, and vouchers that enable our customers to save money on medical products and services. The Company’s processes are monitored by third parties who collect revenues from clients on a per activity basis and report and forward the revenue to the Company’s account.
	Research and Development
	The Company’s key members are part of a continual research development team and monitor new technologies, trends, services and partnerships that can provide the Company with additional services, value to healthcare and pharmaceutical industries and to the patients it serves.
	The Company seeks to educate team members through understanding of all market dynamics that have the potential to affect the business both short term and longer term. The primary goal is to help patients better afford and access the medicines their doctor prescribes, as well as other healthcare products and services they need. Based on this, the Company continually seeks better ways to meet this mission through technology, better user experiences and new ways to engage industries to provide new support for patients needing their products. The Company is always seeking new services and solutions to offer. At this time, the three current platforms provide robust opportunities and growth during the next five years.
	Income Taxes
	Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
	Concentration of Credit Risks
	The Company maintains its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences financial difficulties.
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the depreciable lives of such assets and the allowance for doubtful accounts receivable. Actual results could differ from these estimates.
	Earnings Per Common and Common Equivalent Share
	The computation of basic earnings per common share is computed using the weighted average number of common shares outstanding during the year. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus common stock equivalents which would arise from the exercise of warrants outstanding using the treasury stock method and the average market price per share during the year. Options, warrants and convertible preferred stock which are common stock equivalents are included in the per share calculation for the three and nine months ended September 30, 2013. They have not been included in the diluted earnings per share calculation for the three and nine months ended September 30, 2012 since their effect is anti-dilutive.
	Impairment of Long-Lived Assets
	The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.
	Recently Issued Accounting Guidance
	The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

PREPAID_EXPENSES

PREPAID EXPENSES	9 Months Ended
	Sep. 30, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
PREPAID EXPENSES	'
	Prepaid expenses consisted of the following as of September 30, 2013 and December 31, 2012:
		2013		2012
	Insurance	$	6,653	$	6,437
	Rent		5,049		5,049
	Consulting		14,634		31,672
	Legal		0		25,000
	Total prepaid expenses	$	26,336	$	68,158

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
PROPERTY AND EQUIPMENT	'
	The Company owned equipment recorded at cost which consisted of the following as of September 30, 2013 and December 31, 2012:
		2013			2012
	Computer equipment	$	22,360		$	22,360
	Furniture and fixtures		11,088			11,088
	Subtotal		33,448			33,448
	Accumulated depreciation		(16,984	)		(12,763	)
	Property and equipment, net	$	16,464		$	20,685
	Depreciation expense was $1,407 and $1,382 for the three months ended September 30, 2013 and 2012, respectively. Depreciation expense was $4,221 and $4,094 for the nine months ended September 30, 2013 and 2012, respectively.

WEB_DEVELOPMENT_COSTS

WEB DEVELOPMENT COSTS	9 Months Ended
	Sep. 30, 2013
Notes to Financial Statements	'
WEB DEVELOPMENT COSTS	'
	The Company has capitalized costs in developing their website and web-based products, which consisted of the following as of September 30, 2013 and December 31, 2012:
		2013			2012
	OptimizeRx web development	$	154,133		$	154,133
	SampleMD web development		602,517			602,517
	SampleMD 2.0		62,280			0
	Subtotal, web development costs		818,930			756,650
	Accumulated amortization		(408,069	)		(310,352	)
	Impairment		(59,083	)		(59,083	)
	Web development costs, net	$	351,778		$	387,215
	Amortization is recorded using the straight-line method over a period of five years. The Company is currently developing an enhanced SampleMD website and has capitalized $62,280. The development is currently in process. It is not completed at September 30, 2013. Accordingly, no amortization has been recorded. The development is expected to be completed in 2014. The Company determined that the original OptimizeRx website was no longer useful so the remaining unamortized balance of $59,083 was impaired as of December 31, 2010. Amortization expense for the web development costs was $32,572 and $31,677 for the three months ended September 30, 2013 and 2012, respectively. Amortization expense for the web development costs was $97,717 and $94,964 for the nine months ended September 30, 2013 and 2012, respectively.

PATENT_RIGHTS_AND_INTANGIBLE_A

PATENT RIGHTS AND INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
PATENT RIGHTS AND INTANGIBLE ASSETS	'
	On April 26, 2010, the Company acquired from an officer and shareholder the technical contributions and assignment of all exclusive rights to and for the SampleMD patent currently in process in exchange for 300,000 shares of common stock to be granted at the discretion of the seller in addition to 200,000 stock options valued at $360,000. The shares were valued on the grant date at $570,000 and have been recorded as a payable to the related party.
	The Company has capitalized costs in purchasing and defending the SampleMD patent, which consisted of the following as of September 30, 2013 and December 31, 2012:
		2013			2012
	Patent rights and intangible assets	$	930,000		$	930,000
	Patent defense costs		38,278			0
	Accumulated amortization		(179,388	)		(136,764	)
	Patent rights and intangible assets, net	$	788,890		$	793,236
	The Company began amortizing the patent, using the straight-line method over the estimated useful life of 17 years, once it was put into service in July 2010. In 2013, the Company began incurring costs related to defense of the patent. These costs have been capitalized and will be amortized using the straight-line method over the remaining useful life of the original patent. Amortization expense was $14,246 and $13,676 for the three months ended September 30, 2013 and 2012, respectively. Amortization expense was $42,624 and $41,029 for the nine months ended September 30, 2013 and 2012, respectively.

ACCRUED_EXPENSES

ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
ACCRUED EXPENSES	'
	On January 14, 2013, the Company hired a new CEO. The employment agreement required annual compensation of $175,000 that was to be accrued and deferred until at least January 1, 2014. Additionally, the agreement required the issuance of 2,000,000 options with an exercise price of $1.00 for a term of five years. The options were not exercisable until at least January 1, 2014. On September 20, 2013, the Company entered into a separation agreement with the CEO. As part of the agreement, the accrued compensation was paid through the date of separation and the options were terminated.
	Accrued expenses consisted of the following as of September 30, 2013 and December 31, 2012:
		2013		2012
	Accrued compensation	$	0	$	0
	Accrued audit fees		0		6,000
	Total accrued expenses	$	0	$	6,000

DEFERRED_REVENUE

DEFERRED REVENUE	9 Months Ended
	Sep. 30, 2013
Revenue Recognition [Abstract]	'
DEFERRED REVENUE	'
	The Company has signed several contracts with customers for either the distribution or redemption of coupons. The payments are not taken into revenue until either the coupon is distributed to a patient or the coupon has been redeemed depending on the specific contract. The distributions and redemptions are tracked by the Company’s administrative tool. Additionally, customer setup contracts that have been paid in full are deferred until the Company has completed the obligations of the contacts. Deferred revenue was $13,272 and $49,252 as of September 30, 2013 and December 31, 2012, respectively.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	During the year ended December 31, 2010, the Company acquired from an officer and shareholder the technical contributions and assignment of all exclusive rights to and for the SampleMD patent currently in process in exchange for 300,000 shares of common stock to be granted at the discretion of the seller in addition to 200,000 stock options valued at $360,000. The shares were valued on the grant date at $570,000 and have been recorded as a payable to the related party.

COMMON_STOCK

COMMON STOCK	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
COMMON STOCK	'
	OptimizeRx Corporation has 500,000,000 shares of $.001 par value common stock authorized as of September 30, 2013.
	There were 14,752,496 and 14,232,496 common shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively.
	On June 1, 2012, the Company entered into a consulting agreement with North Coast Advisors, Inc. for various services. The Company agreed to issue 40,000 shares of common stock as of the date of the contract. However, these shares were not issued until July 12, 2012. The Company also agreed to issue an additional 40,000 shares every six months in alignment with the agreement renewal up to the two years of the agreement. The first 40,000 shares were valued at the Company’s common stock price as of the date of the contract, which was $1.12/share and has been expensed. No additional shares were issued and the agreement was voided and replaced by a new agreement as noted below.
	On June 1, 2013, the Company entered into a consulting agreement with North Coast Advisors, Inc. for various services. The Company agreed to issue 20,000 shares of common stock as of the date of the contract. The Company also agreed to issue an additional 20,000 shares every six months in alignment with the agreement renewal up to the two years of the agreement. The first 20,000 shares were valued at the Company’s common stock price as of the date of the contract, which was $1.945/share and has been expensed.
	On September 20, 2013, the Company entered into a separation agreement that includes post-employment consulting services with a former officer. The Company agreed to issue 500,000 shares of common stock, 250,000 shares immediately and 250,000 by January 1, 2014. The first 250,000 shares have been issued and the Company has recognized the entire issuance in the September 30, 2013 shares outstanding. The shares were valued at $505,000 and $233,077 of that amount has been recorded as deferred stock compensation as of September 30, 2013.

PREFERRED_STOCK

PREFERRED STOCK	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
PREFERRED STOCK	'
	Series A Preferred
	During the year ended December 31, 2008, 35 preferred shares were issued for $3,500,000. Issuance costs totaled $515,000 resulting in net proceeds of $2,985,000. The 35 shares are convertible to 3,500,000 shares of common stock and bear a 10% cumulative dividend. In addition, there was a warrant issued to purchase 6,000,000 shares of common stock at an exercise price of $2 for a period of seven years.
	Series A Preferred Continued
	The holders of the preferred stock are entitled to semi-annual dividends payable on the stated value of the Series A preferred stock at a rate of 10% per annum, which shall be cumulative, and accrue daily from the issuance date. The dividends may be paid in cash or shares of the Company's common stock at management’s discretion. If after the conversion eligibility date, the market price for the common stock for any ten consecutive trading days in which the stock trades for over $2 per share and trading exceeds 100,000 shares per day, the preferred shareholders can be required to convert their shares to common stock. Each share of Series A preferred stock shall also be convertible at the option of the holder into that number of shares of common stock of the Company at the stated value of such share at a $1 conversion price.
	The holder may cause this conversion at the time the shares are eligible for resale by the holder. The conversion price is subject to adjustment as hereinafter provided, at any time, or from time to time upon the terms and in the manner hereinafter set forth in the shareholder agreement. There is no conversion expiration date, however, the holder must provide 30 days notice for the registration of the conversion.
	On May 12, 2010, the Company’s Board declared and issued 236,598 common shares as payment for all cumulative and current semi-annual dividends. On November 16, 2010, the Company’s Board declared and issued 173,922 common shares for its semi-annual dividend payment. On March 25, 2011, the Company’s Board declared and issued 176,768 common shares for its semi-annual dividend payment. On September 21, 2011, the Company's Board declared and issued 156,306 common shares for its semi-annual dividend payment. The Company has undeclared dividends that were due in February and September 2012 totaling $350,000 and undeclared dividends of $350,000 that were due in February and September 2013 for a total undeclared amount of $700,000 as of September 30, 2013.
	Series B Preferred
	During the year ended December 31, 2010, 15 preferred shares were issued for $1,500,000. The 15 shares are convertible to 1,000,000 shares of common stock and bear a 10% cumulative dividend. In addition, there was a warrant issued to purchase 3,000,000 shares of common stock at an exercise price of $3 for a period of seven years.
	The preferred stock was issued for $1,500,000 less associated issuance costs of $350,000 for net proceeds of $1,150,000. Additionally, 3,000,000 common stock warrants were issued with the preferred stock. Based on the fair values of the preferred stock and common stock warrants on the issue date, $341,100 was allocated to preferred stock and $1,158,900 was allocated to the common stock warrants. Equity issuance costs of $350,000 were allocated to the preferred stock.
	During the quarter ended September 30, 2011, 15 preferred shares were issued to an investor for $1,500,000. The 15 shares are convertible to 1,000,000 shares of common stock and bear a 10% cumulative dividend. In addition, there was a warrant issued to purchase 1,000,000 shares of common stock at an exercise price of $3 for a period of seven years. Based on the fair values of the preferred stock and common stock warrants on the issue date, $855,460 was allocated to preferred stock and $644,540 was allocated to the common stock warrants. See Note 12.
	Series B Preferred Continued
	The holders of the preferred stock are entitled to semi-annual dividends payable on the stated value of the Series B preferred stock at a rate of 10% per annum, which shall be cumulative, and accrue daily from the issuance date. The dividends may be paid in cash or shares of the Company's common stock at management’s discretion. If after the conversion eligibility date, the market price for the common stock for any ten consecutive trading days in which the stock trades for over $2 per share and trading exceeds 100,000 shares per day, the preferred shareholders can be required to convert their shares to common stock. Each share of Series B preferred stock shall also be convertible at the option of the holder into that number of shares of common stock of the Company at the stated value of such share at a $1.50 conversion price.
	The holder may cause this conversion at the time the shares are eligible for resale by the holder. The conversion price is subject to adjustment as hereinafter provided, at any time, or from time to time upon the terms and in the manner hereinafter set forth in the shareholder agreement. On March 25, 2011, the Company’s Board declared and issued 75,758 common shares for its semi-annual dividend payment. On September 21, 2011, the Company's Board declared and issued 66,988 common shares for its semi-annual dividend payment. The Company has undeclared dividends that were due in February and September 2012 totaling $150,000 and undeclared dividends of $150,000 that were due in February and September 2013 for a total undeclared amount of $300,000 as of September 30, 2013.

STOCK_OPTIONS_AND_WARRANTS

STOCK OPTIONS AND WARRANTS	9 Months Ended
	Sep. 30, 2013
Notes to Financial Statements	'
STOCK OPTIONS AND WARRANTS	'
	The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values.
	The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options and warrants issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option or warrant, whichever can be more clearly determined. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered.
	On May 31, 2011, the Company issued 285,000 stock options to 3 employees at an exercise price of $1.00. The options were valued on the grant date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 218%, risk-free interest rate of 1.68% and expected life of 60 months. The total value of the options was $320,585. The options vest over one year. The Company recognized share-based compensation expense of $187,005 during the year ended December 31, 2011. The remaining balance of $133,580 was recognized over the first five months of 2012.
	During the quarter ended December 31, 2011, the Company issued 20,000 stock options to 2 employees at an exercise price of $1.00. The options were valued on the grant date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 204-205%, risk-free interest rate of 0.88-0.93% and expected life of 60 months. The total value of the options was $19,270. The options vest over one year. The Company recognized share-based compensation expense of $2,480 during the year ended December 31, 2011 and $14,459 during the nine months ended September 30, 2012. The remaining balance was recognized during the remainder of 2012.
	On November 21, 2011, the Company issued 100,000 stock options to an individual at an exercise price of $0.73. The options were valued on the grant date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 205%, risk-free interest rate of 0.92% and expected life of 60 months. The Company recognized expenses of $8,346 during the year ended December 31, 2011 and $75,117 during the nine months ended September 30, 2012. The remaining balance was recognized during the remainder of 2012.
	During the quarter ended March 31, 2012, the Company issued 50,000 stock options to 4 non-employees at an exercise price of $0.89. The options were valued on the grant date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 198%, risk-free interest rate of 0.65% and expected life of 48 months. The total value of the options was $35,091. The options vest over 4 months. The Company recognized share-based compensation expense of $35,091 during the six months ended June 30, 2012.
	During the quarter ended December 31, 2012, the Company issued 25,000 stock options to a non-employee at an exercise price of $1.58. The options were valued on the grant date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 200%, risk-free interest rate of 0.67% and expected life of 60 months. The total value of the options was $40,007. The options vest over 1 year. The Company recognized share-based compensation expense of $8,335 during the three months ended December 31, 2012 and $30,006 during the nine months ended September 30, 2013. The remaining balance will be recognized over the remainder of 2013.
	The Company had the following options outstanding as of September 30, 2013:
			Number of Options			Weighted average
						exercise price
		Outstanding, January 1, 2012		405,000		$	1.01
		Granted - 2012		75,000			1.17
		Exercised - 2012		0			0
		Expired - 2012		(455,000	)		(.98	)
		Balance, December 31, 2012		25,000			1.58
		Granted - 2013		0			0
		Exercised - 2013		0			0
		Expired - 2013		0			0
		Balance, September 30, 2013		25,000		$	1.58
	The Company had the following warrants outstanding as of September 30, 2013:
			Number of Warrants			Weighted average exercise price
		Outstanding, January 1, 2012		14,344,434		$	2.41
		Granted - 2012		0			0
		Exercised - 2012		0			0
		Expired - 2012		0			0
		Balance, December 31, 2012		14,344,434			2.41
		Granted - 2013		0			0
		Exercised - 2013		0			0
		Expired - 2013		(672,000	)		(2.59	)
		Balance, September 30, 2013		13,672,434		$	2.44

OPERATING_LEASES

OPERATING LEASES	9 Months Ended
	Sep. 30, 2013
Leases [Abstract]	'
OPERATING LEASES	'
	The Company signed a lease for new office space on December 1, 2011 at an approximate rent of $5,000 per month. The new offices are in Rochester, Michigan. The lease is for three years with an option to renew for an additional two years at approximately $5,200 per month with six months advance notice to exercise the option. Minimum annual rent is as follows for the initial term of the lease:
		Year ended December 31, 2013	$	60,591
		2014		55,542
		2015		0
		Total lease commitment	$	116,133

MAJOR_CUSTOMERS

MAJOR CUSTOMERS	9 Months Ended
	Sep. 30, 2013
Notes to Financial Statements	'
MAJOR CUSTOMERS	'
	The Company had three major customers that accounted for 68% and two major customers that accounted for 50% of the Company’s revenues for the nine months ended September 30, 2013 and 2012, respectively. The Company expects to continue to maintain these relationships with the customers.

INCOME_TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	For the nine months ended September 30, 2013, the Company incurred net income of approximately $260,000 but has no tax liability. The Company began operations in 2007 and has previous net operating loss carry-forwards of approximately $13,843,000 through December 31, 2012. The cumulative loss of approximately $13,583,000 will be carried forward and can be used through the year 2033 to offset future taxable income. In the future, the cumulative net operating loss carry-forward for income tax purposes may differ from the cumulative financial statement loss due to timing differences between book and tax reporting.
	The provision for Federal income tax consists of the following for the nine months ended September 30, 2013 and 2012:
		2013			2012
	Federal income tax (expense) benefit attributable to:
	Current operations	$	(88,000	)	$	102,000
	Valuation allowance		88,000			(102,000	)
	Net provision for federal income tax	$	0		$	0
	The cumulative tax effect at the expected rate of 34% of significant items comprising our net deferred tax amount is as follows as of September 30, 2013 and December 31, 2012:
		2013			2012
	Deferred tax asset attributable to:
	Net operating loss carryover	$	4,618,000		$	4,706,000
	Valuation allowance		(4,618,000	)		(4,706,000	)
	Net deferred tax asset	$	0		$	0
	Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of approximately $13,583,000 for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years.

CONTINGENT_LIABILITY

CONTINGENT LIABILITY	9 Months Ended
	Sep. 30, 2013
Notes to Financial Statements	'
CONTINGENT LIABILITY	'
	On January 14, 2013, the Company hired a new CEO. The employment agreement required annual compensation of $175,000 that was to be accrued and deferred until at least January 1, 2014. Additionally, the agreement required the issuance of 2,000,000 options with an exercise price of $1.00 for a term of five years. The options were not exercisable until at least January 1, 2014, and were only exercisable after reaching certain financial terms and conditions. Due to these restrictions, no accrual was made for the issuance of these options.
	On September 20, 2013, the Company entered into a separation agreement with the CEO. As part of the terms of the separation agreement, the accrued compensation up to the date of separation was paid and the options were terminated. Also as part of the agreement, the Company will be involved with the former CEO in a limited role as a consultant for one year to assist in various initiatives and in transition of various ongoing projects for 500,000 shares of company stock. Half of the value of the shares will be expensed immediately, with the other half expensed over the one year life of the agreement. 7.69% of the second half of the stock value has been expensed at September 30, 2013, with the remainder to be expensed as services are rendered over the remaining life of the agreement. The unamortized balance has been recorded as Deferred Stock Compensation in the equity section of the balance sheet.

OPERATING_EXPENSES

OPERATING EXPENSES	9 Months Ended
	Sep. 30, 2013
Notes to Financial Statements	'
OPERATING EXPENSES	'
	Operating expenses consisted of the following for the three and nine months ended September 30, 2013 and 2012, respectively:
		Three months ended				Nine months ended
		September 30,				September 30,
		2013		2012		2013		2012
	Advertising	$	23,207	$	1,167	$	30,372	$	45,088
	Professional fees		151,610		83,235		275,004		186,188
	Consulting		25,657		0		65,786		7,835
	Salaries, wages and benefits		344,979		299,286		1,040,238		900,751
	Rent		15,148		15,148		45,444		47,214
	Depreciation and amortization		48,225		46,735		144,562		140,087
	Stock-based compensation		281,925		29,857		310,823		227,922
	Revenue share expense		376,831		20,669		614,234		28,804
	General and administrative		94,753		63,208		360,010		197,368
	Total Operating Expenses	$	1,362,335	$	559,305	$	2,886,473	$	1,781,257

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	In accordance with ASC 855-10, the Company has analyzed its operations subsequent to September 30, 2013 through the date these financial statements were issued and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”), and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Form 10-K filed with the SEC as of and for the year ended December 31, 2012. In the opinion of management, all adjustments necessary for the financial statements to be not misleading for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year.
Accounting Basis	'
	Accounting Basis
	The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting). The Company has adopted a December 31 fiscal year end.
Principles of Consolidation	'
	Principles of Consolidation
	The financial statements reflect the consolidated results of OptimizeRx Corporation (a Nevada corporation) and its wholly owned subsidiary OptimizeRx Corporation (a Michigan corporation). All material inter-company transactions have been eliminated in the consolidation.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	For purposes of the accompanying financial statements, the Company considers all highly liquid instruments with an initial maturity of three months or less to be cash equivalents.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The fair value of cash, accounts receivable, prepaid expenses, patent rights, web development costs, accounts payable, accounts payable – related party, accrued expenses and deferred revenue approximates the carrying amount of these financial instruments due to their short-term nature. The fair value of long-term debt, which approximates its carrying value, is based on current rates at which the Company could borrow funds with similar remaining maturities.
Accounts Receivable and Allowance for Doubtful Accounts	'
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates. Bad debt expense was $0 for the nine months ended September 30, 2013 and 2012, respectively. The allowance for doubtful accounts was $0 as of September 30, 2013 and December 31, 2012, respectively.
Property and Equipment	'
	Property and Equipment
	The capital assets are being depreciated over their estimated useful lives, three to seven years using the straight-line method of depreciation for book purposes.
Revenue Recognition	'
	Revenue Recognition
	All revenue is recognized when it is earned. Revenues are generated either through the Company’s website activities, in which we earn revenue from advertising and lead generation activities, or from our SampleMD activities, which include offering setup within the systems and our offers, coupons, and vouchers that enable our customers to save money on medical products and services. The Company’s processes are monitored by third parties who collect revenues from clients on a per activity basis and report and forward the revenue to the Company’s account.
Research and Development	'
	Research and Development
	The Company’s key members are part of a continual research development team and monitor new technologies, trends, services and partnerships that can provide the Company with additional services, value to healthcare and pharmaceutical industries and to the patients it serves.
	The Company seeks to educate team members through understanding of all market dynamics that have the potential to affect the business both short term and longer term. The primary goal is to help patients better afford and access the medicines their doctor prescribes, as well as other healthcare products and services they need. Based on this, the Company continually seeks better ways to meet this mission through technology, better user experiences and new ways to engage industries to provide new support for patients needing their products. The Company is always seeking new services and solutions to offer. At this time, the three current platforms provide robust opportunities and growth during the next five years.
Income Taxes	'
	Income Taxes
	Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
Concentration of Credit Risks	'
	Concentration of Credit Risks
	The Company maintains its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences financial difficulties.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the depreciable lives of such assets and the allowance for doubtful accounts receivable. Actual results could differ from these estimates.
Earnings Per Common and Common Equivalent Share	'
	Earnings Per Common and Common Equivalent Share
	The computation of basic earnings per common share is computed using the weighted average number of common shares outstanding during the year. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus common stock equivalents which would arise from the exercise of warrants outstanding using the treasury stock method and the average market price per share during the year. Options, warrants and convertible preferred stock which are common stock equivalents are included in the per share calculation for the three and nine months ended September 30, 2013. They have not been included in the diluted earnings per share calculation for the three and nine months ended September 30, 2012 since their effect is anti-dilutive.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.
Recently Issued Accounting Guidance	'
	Recently Issued Accounting Guidance
	The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

PREPAID_EXPENSES_Tables

PREPAID EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2013
Notes to Financial Statements	'
Schedule of Prepaid Expenses	'
		2013		2012
	Insurance	$	6,653	$	6,437
	Rent		5,049		5,049
	Consulting		14,634		31,672
	Legal		0		25,000
	Total prepaid expenses	$	26,336	$	68,158

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Schedule of Property and Equipment	'
		2013			2012
	Computer equipment	$	22,360		$	22,360
	Furniture and fixtures		11,088			11,088
	Subtotal		33,448			33,448
	Accumulated depreciation		(16,984	)		(12,763	)
	Property and equipment, net	$	16,464		$	20,685

WEB_DEVELOPMENT_COSTS_Tables

WEB DEVELOPMENT COSTS (Tables)	9 Months Ended
	Sep. 30, 2013
Notes to Financial Statements	'
Schedule of Web Development Costs	'
		2013			2012
	OptimizeRx web development	$	154,133		$	154,133
	SampleMD web development		602,517			602,517
	SampleMD 2.0		62,280			0
	Subtotal, web development costs		818,930			756,650
	Accumulated amortization		(408,069	)		(310,352	)
	Impairment		(59,083	)		(59,083	)
	Web development costs, net	$	351,778		$	387,215

PATENT_RIGHTS_AND_INTANGIBLE_A1

PATENT RIGHTS AND INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Patent and Intangible Assets	'
		2013			2012
	Patent rights and intangible assets	$	930,000		$	930,000
	Patent defense costs		38,278			0
	Accumulated amortization		(179,388	)		(136,764	)
	Patent rights and intangible assets, net	$	788,890		$	793,236

ACCRUED_EXPENSES_Tables

ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Schedule of Accured Expenses	'
		2013		2012
	Accrued compensation	$	0	$	0
	Accrued audit fees		0		6,000
	Total accrued expenses	$	0	$	6,000

STOCK_OPTIONS_AND_WARRANTS_Tab

STOCK OPTIONS AND WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2013
Notes to Financial Statements	'
Schedule of Stock Options	'
			Number of Options			Weighted average
						exercise price
		Outstanding, January 1, 2012		405,000		$	1.01
		Granted - 2012		75,000			1.17
		Exercised - 2012		0			0
		Expired - 2012		(455,000	)		(.98	)
		Balance, December 31, 2012		25,000			1.58
		Granted - 2013		0			0
		Exercised - 2013		0			0
		Expired - 2013		0			0
		Balance, September 30, 2013		25,000		$	1.58
Schedule of Warrants	'
			Number of Warrants			Weighted average exercise price
		Outstanding, January 1, 2012		14,344,434		$	2.41
		Granted - 2012		0			0
		Exercised - 2012		0			0
		Expired - 2012		0			0
		Balance, December 31, 2012		14,344,434			2.41
		Granted - 2013		0			0
		Exercised - 2013		0			0
		Expired - 2013		(672,000	)		(2.59	)
		Balance, September 30, 2013		13,672,434		$	2.44

OPERATING_LEASES_Tables

OPERATING LEASES (Tables)	9 Months Ended
	Sep. 30, 2013
Leases [Abstract]	'
Schedule of Rent Expense	'
		Year ended December 31, 2013	$	60,591
		2014		55,542
		2015		0
		Total lease commitment	$	116,133

INCOME_TAXES_Tables

INCOME TAXES (Tables)	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Federal Income Tax	'
		2013			2012
	Federal income tax (expense) benefit attributable to:
	Current operations	$	(88,000	)	$	102,000
	Valuation allowance		88,000			(102,000	)
	Net provision for federal income tax	$	0		$	0
Deferred Tax Asset	'
		2013			2012
	Deferred tax asset attributable to:
	Net operating loss carryover	$	4,618,000		$	4,706,000
	Valuation allowance		(4,618,000	)		(4,706,000	)
	Net deferred tax asset	$	0		$	0

OPERATING_EXPENSES_Tables

OPERATING EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2013
Notes to Financial Statements	'
Schedule of Operating Expenses	'
		Three months ended				Nine months ended
		September 30,				September 30,
		2013		2012		2013		2012
	Advertising	$	23,207	$	1,167	$	30,372	$	45,088
	Professional fees		151,610		83,235		275,004		186,188
	Consulting		25,657		0		65,786		7,835
	Salaries, wages and benefits		344,979		299,286		1,040,238		900,751
	Rent		15,148		15,148		45,444		47,214
	Depreciation and amortization		48,225		46,735		144,562		140,087
	Stock-based compensation		281,925		29,857		310,823		227,922
	Revenue share expense		376,831		20,669		614,234		28,804
	General and administrative		94,753		63,208		360,010		197,368
	Total Operating Expenses	$	1,362,335	$	559,305	$	2,886,473	$	1,781,257

NATURE_OF_BUSINESS_Details_Nar

NATURE OF BUSINESS (Details Narrative)	9 Months Ended
	Sep. 30, 2013	Apr. 18, 2008
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'
Date of Organization	31-Jan-06	'
Date of Incorporation	22-Oct-07	'
Capital stock of OptimizeRx Corporation exchanged for common stock of RFID, Ltd	'	1,256,958
Ownership of outstanding capital stock of RFID, Ltd.	'	100.00%

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Accounting Policies [Abstract]	'	'	'
Fiscal Year End	'--12-31	'	'
Bad Debt Expense	$0	$0	'
Allowance for doubtful accounts	$0	'	$0
Capital Assets Useful Life, Minimum	'3 years	'	'
Capital Assets Useful Life, Maximum	'7 years	'	'

PREPAID_EXPENSES_Schedule_of_P

PREPAID EXPENSES - Schedule of Prepaid Expenses (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'	'
Insurance	$6,653	$6,437
Rent	5,049	5,049
Consulting	14,634	31,672
Legal	0	25,000
Total prepaid expenses	$26,336	$68,158

PROPERTY_AND_EQUIPMENT_Schedul

PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]	'	'
Computer equipment	$22,360	$22,360
Furniture and fixtures	11,088	11,088
Subtotal	33,448	33,448
Accumulated depreciation	-16,984	-12,763
Property and equipment, net	$16,464	$20,685

PROPERTY_AND_EQUIPMENT_Details

PROPERTY AND EQUIPMENT (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Property, Plant and Equipment [Abstract]	'	'	'	'
Depreciation	$1,407	$1,382	$4,221	$4,094

WEB_DEVELOPMENT_COSTS_Schedule

WEB DEVELOPMENT COSTS - Schedule of Web Development Costs (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Notes to Financial Statements	'	'
OptimizeRx web development	$154,133	$154,133
SampleMD web development	602,517	602,517
SampleMD 2.0	62,280	0
Subtotal, web development costs	818,930	756,650
Accumulated amortization	-408,069	-310,352
Impairment	-59,083	-59,083
Web development costs, net	$351,778	$387,215

WEB_DEVELOPMENT_COSTS_Details_

WEB DEVELOPMENT COSTS (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Notes to Financial Statements	'	'	'	'	'
Useful Life of Website	'	'	'5 years	'	'
SampleMD 2.0	$62,280	'	$62,280	'	$0
Unamortized Debt Issuance Expense	-59,083	'	-59,083	'	-59,083
Amortization Expense of Website	$32,572	$31,677	$97,717	$94,964	'

PATENT_RIGHTS_AND_INTANGIBLE_A2

PATENT RIGHTS AND INTANGIBLE ASSETS - Schedule of Patent and Intangible Assets (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
Patent rights and intangible assets	$930,000	$930,000
Patent defense costs	38,278	0
Accumulated amortization	-179,388	-136,764
Patent rights and intangible assets, net	$788,890	$793,236

PATENT_RIGHTS_AND_INTANGIBLE_A3

PATENT RIGHTS AND INTANGIBLE ASSETS (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Apr. 26, 2010
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'	'
Common stock shares granted to acquire exclusive patent rights	'	'	'	'	300,000
Options granted to acquire exclusive patent rights	'	'	'	'	200,000
Options granted to acquire exclusive patent rights, value	'	'	'	'	$360,000
Common stock shares granted to acquire exclusive patent rights, value	'	'	'	'	570,000
Useful life of Patent	'	'	'17 years	'	'
Amortization Expense of Patent	$14,246	$13,676	$42,624	$41,029	'

ACCRUED_EXPENSES_Schedule_of_A

ACCRUED EXPENSES - Schedule of Accured Expenses (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Payables and Accruals [Abstract]	'	'
Accrued compensation	$0	$0
Accrued audit fees	0	6,000
Total accrued expenses	$0	$6,000

ACCRUED_EXPENSES_Details_Narra

ACCRUED EXPENSES (Details Narrative) (USD $)	Jan. 14, 2013
Payables and Accruals [Abstract]	'
Annual Compensation for CEO	$175,000
Issuance of stock options to CEO, shares	2,000,000
Issuance of stock options to CEO, par value	1
Term of options agreement	'5 years
Exercisable date	1-Jan-14

DEFERRED_REVENUE_Details_Narra

DEFERRED REVENUE (Details Narrative) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Revenue Recognition [Abstract]	'	'
Deferred revenue	$13,272	$49,252

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)	Dec. 31, 2012
Related Party Transactions [Abstract]	'
Share Based Compensation Arrangement of Stock Options Issued	300,000
Common Stock Issued For Purchase Of Patent	200,000
Share Based Compensation Arrangement of Stock Options Value	$360,000
Common Stock Value On Grant Date	$570,000

COMMON_STOCK_Details_Narrative

COMMON STOCK (Details Narrative) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Jun. 01, 2013	Jul. 12, 2012	Jun. 01, 2012	Jan. 02, 2014	Sep. 20, 2013
			North Coast Advisors	North Coast Advisors	North Coast Advisors	Separation Agreement	Separation Agreement
Common Stock Shares Authorized	500,000,000	500,000,000	'	'	'	'	'
Common Stock Par Value Per Share	$0.00	$0.00	'	'	'	'	'
Common Stock Shares Issued	14,752,496	14,232,496	'	'	'	'	'
Shares Issued	'	'	20,000	40,000	40,000	250,000	250,000
Shares Issued, per share value	'	'	$1.95	$1.12	'	'	'
Term of Agreement	'	'	'P2Y	'	'P2Y	'	'
Shares Issued, value	$14,752	$14,232	'	'	'	'	$505,000
Deferred stock compensation	($233,077)	$0	'	'	'	'	($233,077)

PREFERRED_STOCK_Details_Narrat

PREFERRED STOCK (Details Narrative) (USD $)

3 Months Ended

12 Months Ended

Sep. 30, 2011

Dec. 31, 2010

Dec. 31, 2008

Sep. 21, 2011

Mar. 25, 2011

Nov. 16, 2010

12-May-10

Sep. 30, 2013

Sep. 30, 2012

Feb. 29, 2012

Sep. 30, 2013

Sep. 30, 2012

Feb. 29, 2012

Series A

Series A

Series A

Series B

Series B

Series B

Preferred Stock Series A Stock Share Issued For Proceeds

'

'

35

'

'

'

'

'

'

'

'

'

'

Preferred Stock Series A Value

'

'

$3,500,000

'

'

'

'

'

'

'

'

'

'

Preferred Stock Series A Stock Issuance Expense

'

'

515,000

'

'

'

'

'

'

'

'

'

'

Preferred Stock Series A Stock Net Proceeds

'

'

2,985,000

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock Series A Shares Issued Upon Conversion

'

'

3,500,000

'

'

'

'

'

'

'

'

'

'

Preferred Stock Series A Stock Dividend Rate Percentage

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

Common Stock Warrants Issued For Purchase

1,000,000

3,000,000

6,000,000

'

'

'

'

'

'

'

'

'

'

Common Stock Warrants Exercise Price

3

3

2

'

'

'

'

'

'

'

'

'

'

Common Stock Warrants Expiration

'7 years

'7 years

'7 years

'

'

'

'

'

'

'

'

'

'

Common Stock Shares Issued For Dividend Payment

'

'

'

156,306

176,768

173,922

236,598

'

'

'

'

'

'

Preferred Stock Series B Shares Issued For Proceeds

15

15

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock Series B Value

1,500,000

1,500,000

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock Series B Shares Issued Upon Conversion

1,000,000

1,000,000

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock Series B Stock Dividend Rate Percentage

10.00%

10.00%

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock Series B Stock Issuance Expense

'

350,000

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock Series B Stock Net Proceeds

'

1,150,000

'

'

'

'

'

'

'

'

'

'

'

Common Stock Warrants Issued

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock Value On Grant Date

855,460

341,100

'

'

'

'

'

'

'

'

'

'

'

Common Stock Warrant Value On Grant Date

644,540

1,158,900

'

'

'

'

'

'

'

'

'

'

'

Common Stock Shares Issued For Dividend Payment For Series B

'

'

'

66,988

75,758

'

'

'

'

'

'

'

'

Undeclared dividends

'

'

'

'

'

'

'

$700,000

$350,000

$350,000

$300,000

$150,000

$150,000

STOCK_OPTIONS_AND_WARRANTS_Sch

STOCK OPTIONS AND WARRANTS - Schedule of Stock Options (Details)	12 Months Ended
	Dec. 31, 2012	Sep. 30, 2013
Notes to Financial Statements	'	'
Beginning Balance, number of shares	405,000	25,000
Beginning Balance, weighted average exercise price	1.01	1.58
Options granted, number of shares	75,000	'
Options granted, weighted average exercise price	1.17	'
Options exercised, number of shares	0	'
Options exercised, weighted average exercise price	0	'
Options expired, number of shares	-455,000	'
Options expired, weighted average exercise price	-0.98	'
Ending Balance, number of shares	25,000	25,000
Ending Balance, weighted average exercise price	1.58	1.58

STOCK_OPTIONS_AND_WARRANTS_Sch1

STOCK OPTIONS AND WARRANTS - Schedule of Warrants (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Notes to Financial Statements	'	'
Beginning Balance, number of shares	14,344,434	14,344,434
Beginning Balance, weighted average exercise price	$2.41	$2.41
Warrants granted, number of shares	0	0
Warrants granted, weighted average exercise price	$0	$0
Warrants exercised, number of shares	0	0
Warrants exercised, weighted average exercise price	$0	$0
Warrants expired, number of shares	-672,000	0
Warrants expired, weighted average exercise price	($2.59)	$0
Ending Balance, number of shares	13,672,434	14,344,434
Ending Balance, weighted average exercise price	$2.44	$2.41

STOCK_OPTIONS_AND_WARRANTS_Det

STOCK OPTIONS AND WARRANTS (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Share Based Compensation Expense	$281,925	$29,857	$310,823	$227,922
Two Employees Stock Options	'	'	'	'
Share Based Compensation Expense	'	'	'	14,459
Individual Stock Options	'	'	'	'
Share Based Compensation Expense	'	'	'	75,117
Non-Employee Stock Options	'	'	'	'
Share Based Compensation Expense	'	'	$30,006	'

Schedule_of_Rent_Expense_Detai

Schedule of Rent Expense (Details) (USD $)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Leases [Abstract]	'	'	'
Minimum Annual Lease Amount	$0	$55,542	$60,591
Total 3 year Lease Commitment	'	'	$116,133

OPERATING_LEASES_Details_Narra

OPERATING LEASES (Details Narrative) (USD $)	9 Months Ended
	Sep. 30, 2013
Leases [Abstract]	'
Monthly Rent Due	$5,000
Term Of Lease	'3 years
Monthly Rent Option	$5,200

MAJOR_CUSTOMERS_Details_Narrat

MAJOR CUSTOMERS (Details Narrative)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Notes to Financial Statements	'	'
Major Customers	63.00%	53.00%

INCOME_TAXES_Federal_Income_Ta

INCOME TAXES - Federal Income Tax (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Federal income tax (expense) benefit attributable to:	'	'
Current operations	($88,000)	$102,000
Valuation allowance	88,000	-102,000
Net provision for federal income tax	$0	$0

INCOME_TAXES_Deferred_Tax_Asse

INCOME TAXES - Deferred Tax Asset (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Deferred tax asset attributable to:	'	'
Net operating loss carryover	$4,618,000	$4,706,000
Valuation allowance	-4,618,000	-4,706,000
Net deferred tax asset	$0	$0

INCOME_TAXES_Details_Narrative

INCOME TAXES (Details Narrative) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Operating Income Loss	$260,000	'
Operating Loss Carryforwards	$13,583,000	$13,843,000
Carryforward Expiration Date	1-Jan-33	'
Effective Income Tax Rate	34.00%	'

CONTINGENT_LIABILITY_Details_N

CONTINGENT LIABILITY (Details Narrative) (USD $)	Jan. 14, 2013	Jan. 02, 2014	Sep. 20, 2013
		Separation Agreement	Separation Agreement
Annual Compensation for CEO	$175,000	'	'
Issuance of stock options to CEO, shares	2,000,000	'	'
Issuance of stock options to CEO, par value	1	'	'
Term of options agreement	'5 years	'	'
Exercisable date	1-Jan-14	'	'
Shares Issued	'	250,000	250,000

OPERATING_EXPENSES_Schedule_of

OPERATING EXPENSES - Schedule of Operating Expenses (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Notes to Financial Statements	'	'	'	'
Advertising	$23,207	$1,167	$30,372	$45,088
Professional fees	151,610	83,235	275,004	186,188
Consulting	25,657	0	65,786	7,835
Salaries, wages and benefits	344,979	299,286	1,040,238	900,751
Rent	15,148	15,148	45,444	47,214
Depreciation and amortization	48,225	46,735	144,562	140,087
Stock-based compensation	281,925	29,857	310,823	227,922
Revenue share expense	376,831	20,669	614,234	28,804
General and administrative	94,753	63,208	360,010	197,368
Total Operating Expenses	$1,362,335	$559,305	$2,886,473	$1,781,257